Search

Displaying results 5881 - 5890 of 8009 in total
  1. Drug

    IMT-288

    go.drugbank.com/drugs/DB19068
    Investigational

    IMT-288 is under investigation in clinical trial NCT01730638 (Immunotep for Patients With Medullary Thyroid Carcinoma.).

  2. Drug

    Ensovibep

    go.drugbank.com/drugs/DB19078
    Investigational

    Ensovibep is under investigation in clinical trial NCT04501978 (ACTIV-3: Therapeutics for Inpatients With COVID-19).

  3. Drug

    AB-207

    go.drugbank.com/drugs/DB22801
    Investigational

    AB-207 is under investigation in clinical trial NCT06456073 (E-CEL UVEC Treatment for Anal Fissures).

  4. Drug

    TG-100801

    go.drugbank.com/drugs/DB05075
    Investigational

    TG100801 is a topically applied kinase inhibitor in macular degeneration patients. It is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammati...

  5. Drug

    DS-2325a

    go.drugbank.com/drugs/DB18134
    Investigational

    DS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome.

  6. Drug

    Methfuroxam

    go.drugbank.com/drugs/DB16231
    Investigational

    Methfuroxam is under investigation in clinical trial NCT01213407 (Dendritic Cell Cancer Vaccine for High-grade Glioma).

  7. Drug

    SB-705498

    go.drugbank.com/drugs/DB11883
    Investigational

    SB-705498 has been investigated for the treatment of Rhinitis, Chronic Cough, and Non-allergic Rhinitis.

  8. Drug

    SCY-635

    go.drugbank.com/drugs/DB12451
    Investigational

    SCY-635 has been investigated for the treatment of Chronic Hepatitis C and Hepatitis C Infection.

  9. Drug

    Chlorophetanol

    go.drugbank.com/drugs/DB11368
    Experimental

    Chlorophetanol is an agent known to have antifungal activities.

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  10. Drug

    BTA9881

    go.drugbank.com/drugs/DB05226
    Investigational

    BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.